Companies › SLXN

SILEXION THERAPEUTICS CORP (SLXN)

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0002022416 · EDGAR filings · Updated 2026-07-21

SILEXION THERAPEUTICS CORP (SLXN) has reported institutional ownership of 70.2%, with 19 institutional managers holding positions valued at $62.0K per the latest 13F reporting period. SEC filings include an active notice of delisting or failure to satisfy a continued listing rule (8-K Item 3.01), substantial-doubt (going concern) disclosure per the filings.

Latest updates

• 2026-07-21 — Current report (8-K) filed
• 2026-07-13 — DEFA14A filed
• 2026-06-23 — SCHEDULE 13D/A filed
• 2026-06-18 — EFFECT filed
• 2026-06-18 — Prospectus supplement (424B3) filed
• 2026-06-16 — Proxy statement (DEF 14A) filed

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, SILEXION THERAPEUTICS CORP has 19 institutional holders and institutional ownership of 70.2%.

Insider activity

Insiders reported 16 transactions (0 buys, 1 sells) across 9 reporting insiders, with a net reported value of −$31.0K.

Data flags from SEC filings

Related companies

GRI Bio Inc (GRI) · Adial Pharmaceuticals Inc (ADIL) · BGM Group Ltd (BGM) · LYRA THERAPEUTICS INC (LYRA) · PROPANC BIOPHARMA INC (PPCB) · Check Cap Ltd (MBAI)